leisure time -WSS

leisure time

author：fashion 2025-09-28 03:21:14 - browse：69339

Obesity conference attendees with a pink and blue Wegovy sign hanging from the ceiling above. -- obesity coverage from STAT — Wegovy, the obesity drug, was inescapable at the ObesityWeek conference in Dallas. Elaine Chen

DALLAS — Here at ObesityWeek, one of the largest conferences on obesity, Novo Nordisk and Eli Lilly are displaying more than a dozen studies that together carry the message: Our blockbuster weight loss treatments will be worth it for society.

But experts point out that much of this company-funded research does not include the cost of the drugs themselves, which sell at more than $10,000 per year in the U.S. and are meant to be taken indefinitely.

The two major pharmaceutical companies have seen interest skyrocket for their GLP-1-based drugs like Ozempic, Wegovy, and Mounjaro, a new generation of medications that can cut substantial amounts of weight. But insurance plans have been slow to grant wide access to obesity treatments, concerned that the vast amount of people eligible to take them, along with their high price, could lead to significant financial strain.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： Readout Newsletter: The latest at Gilead, Catalent, and the NIH

explore

WSS

Drug cartel violence flares in western Mexico after vigilante leader's killing

Archived: an online chat discussing Ebola, vaccines, and a new epidemic

PBM reforms clear House panel

Congress must reauthorize a committee to support older Americans

Hubble vs. James Webb telescope images: See the difference

Readout Newsletter: Bayer's future, Merck Caraway acquisition, etc

hotspot

leisure time

explore

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Skip the lead apron during X

Alkermes shareholders re

Readout LOUD podcast: A CRISPR milestone, biotech mixology

Alkermes shareholders re

David Sabatini, ex

Moonlake's readout produced a cash windfall. Risks remain

A daunting task: navigating dual Medicare, Medicaid eligibility

23andMe had bad news about my health. I wish a person had delivered it

Readout Newsletter: What is Casgevy? Does Wegovy hurt muscle?

entertainment

Top Ukrainian generals say counteroffensive is 'going to plan' as losses mount

Hospitals look to new technology to keep health care workers safe

Beware reading your test results before your doctor does

Beware reading your test results before your doctor does

Drug cartel violence flares in western Mexico after vigilante leader's killing

Prescription digital therapeutics are key to pharma’s future

knowledge

explore

leisure time

hotspot